A review of dupilumab in the treatment of atopic diseases

被引：68

作者：

Thibodeaux, Quinn ^{[1
]}

Smith, Mary Patricia ^{[1
]}

Ly, Karen ^{[1
]}

Beck, Kristen ^{[1
]}

Liao, Wilson ^{[1
]}

Bhutani, Tina ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Dermatol, 515 Spruce St, San Francisco, CA 94118 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2019年 / 15卷 / 09期

关键词：

Dupilumab; Dupixent; atopic dermatitis; eczema; asthma; IL-4; IL-13; biologic; review; CHRONIC RHINOSINUSITIS; PERSISTENT ASTHMA; DOUBLE-BLIND; DERMATITIS; MODERATE; PLACEBO; ADULTS; PHENOTYPES; EFFICACY; BURDEN;

D O I：

10.1080/21645515.2019.1582403

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Dupilumab is a fully human monoclonal IgG4 antibody directed against the alpha subunit of the IL-4 receptor and prevents the signaling of IL-4 and IL-13, two type 2 cytokines known to be important drivers of atopic diseases. In March of 2017, the United States Food and Drug Administration (FDA) approved dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults that is uncontrolled with topical medications, becoming the first biologic agent approved to treat this chronic skin condition. In October of 2018, Dupilumab received approval by the FDA as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years or older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. This review summarizes the characteristics of dupilumab and the clinical research that has been published to date, including treatment efficacy and adverse events.

引用

页码：2129 / 2139

页数：11

共 38 条

[11]

Brandt E.B., 2011, Journal of Clinical & Cellular Immunology, V2, DOI [10.4172/2155-9899.1000110, DOI 10.4172/2155-9899.1000110]

[12] Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma [J].

Castro, M. ;

Corren, J. ;

Pavord, I. D. ;

Maspero, J. ;

Wenzel, S. ;

Rabe, K. F. ;

Busse, W. W. ;

Ford, L. ;

Sher, L. ;

FitzGerald, J. M. ;

Katelaris, C. ;

Tohda, Y. ;

Zhang, B. ;

Staudinger, H. ;

Pirozzi, G. ;

Amin, N. ;

Ruddy, M. ;

Akinlade, B. ;

Khan, A. ;

Chao, J. ;

Martincova, R. ;

Graham, N. M. H. ;

Hamilton, J. D. ;

Swanson, B. N. ;

Stahl, N. ;

Yancopoulos, G. D. ;

Teper, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) :2486-2496

[13] Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial [J].

Chupp, Geoffrey L. ;

Bradford, Eric S. ;

Albers, Frank C. ;

Bratton, Daniel J. ;

Wang-Jairaj, Jie ;

Nelsen, Linda M. ;

Trevor, Jennifer L. ;

Magnan, Antoine ;

ten Brinke, Anneke .

LANCET RESPIRATORY MEDICINE, 2017, 5 (05) :390-400

[14] Epidemiology of atopic dermatitis: a review [J].

DaVeiga, Sigrid Payne .

ALLERGY AND ASTHMA PROCEEDINGS, 2012, 33 (03) :227-234

[15] Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab [J].

Davis, John D. ;

Bansal, Ashish ;

Hassman, David ;

Akinlade, Bolanle ;

Li, Meng ;

Li, Zhaoyang ;

Swanson, Brian ;

Hamilton, Jennifer D. ;

DiCioccio, A. Thomas .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (06) :1146-1154

[16] Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE) [J].

de Bruin-Weller, M. ;

Thaci, D. ;

Smith, C. H. ;

Reich, K. ;

Cork, M. J. ;

Radin, A. ;

Zhang, Q. ;

Akinlade, B. ;

Gadkari, A. ;

Eckert, L. ;

Hultsch, T. ;

Chen, Z. ;

Pirozzi, G. ;

Graham, N. M. H. ;

Shumel, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) :1083-1101

[17] Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials [J].

Fleming, Patrick ;

Drucker, Aaron M. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (01) :62-+

[18] Commonality of the IL-4/IL-13 pathway in atopic diseases [J].

Gandhi, Namita A. ;

Pirozzi, Gianluca ;

Graham, Neil M. H. .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (05) :425-437

[19] Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis [J].

Guttman-Yassky, Emma ;

Bissonnette, Robert ;

Ungar, Benjamin ;

Suarez-Farinas, Mayte ;

Ardeleanu, Marius ;

Esaki, Hitokazu ;

Suprun, Maria ;

Estrada, Yeriel ;

Xu, Hui ;

Peng, Xiangyu ;

Silverberg, Jonathan I. ;

Menter, Alan ;

Krueger, James G. ;

Zhang, Rick ;

Chaudhry, Usman ;

Swanson, Brian ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Yancopoulos, George D. ;

Hamilton, Jennifer D. D. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (01) :155-172

[20]

Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25

← 1 2 3 4 →